课题基金 / 基金详情

Fundamental research on identification and its control of the priming factor in liver cancer proliferation

Fundamental research on identification and its control of the priming factor in liver cancer proliferation
肝癌增殖启动因子的识别及其调控基础研究
批准号:
14370359
负责人:
UENO Shinichi
金额:
$3.52万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2005

项目摘要

项目成果

UENO Shinichi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
1)In 42 human HCC samples, IL-8 expression and its biological and clinical significance was studied. Using RT-PCR to IL-8 mRNA, 32 HCC samples were positive of IL-8. IL-8 expression of tumor tissue was not correlated with its angiogenesis studied by CD34 immunostaining. Hence, the incidence of vessel involvement was much higher in IL-8 positive group than in IL-8 negative group (n=10). Thus, TNM staging of HCC in positive group was higher than that in negative group. Overall, it is concluded that IL-8 expression in HCC may affect tumor cell behavior more than angiogenesis.2)In rat-hepatocrcinogenesis induced by Diethylnitrosamin (DEN), liver weight and cancer volume were increased at 17-week DEN administration. Moreover, tissue MDA level was increased, and tissue NF-κB activation and the increase of iNOS level were shown. TNP470 (50mg/kg) and Roxithromicin (RXM 100mg/kg) inhibited the NF-κB activation and the following iNOS and MDA level.3)By using nude mouse- dorsal bag model, it is shown that RXM inhibited tumor angiogenesis of HepG2.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
Roxithromycin inhibits constitutive activation of nuclear factor {kappa}B by deminishing oxidative stress in a rat model of hepatocellular carcinoma
罗红霉素通过减少肝细胞癌大鼠模型中的氧化应激来抑制核因子 {kappa}B 的组成性激活
DOI: --
发表时间: 2005
期刊: Clin Cancer Res 11(15):
影响因子: --
作者: [Ueno S, Aoki D, Kudo F, Hiwatashi K, Matsushita K, Oyama T, Maruyama I, Aikou T.]
通讯作者: Aikou T.
Roxithromycin inhibits constitutive activation of nuclear factor {kappa}B by diminishing oxidative stress in a rat model of hepatocellular carcinoma
罗红霉素通过减少肝细胞癌大鼠模型的氧化应激来抑制核因子 {kappa}B 的组成性激活
DOI: --
发表时间: 2005
期刊: Clin Cancer Res. 11(15)
影响因子: --
作者: [Ueno S, Aoki D, Kubo F, Hiwatashi K, Matsushita K, Oyama T, Maruyama I, Aikou T.]
通讯作者: Aikou T.
Roxithromycin inhibits angiogenesis of human hepatoma cells in vivo by suppressing VEGF production.
Roxithromycin 通过抑制 VEGF 的产生来抑制体内人肝癌细胞的血管生成。
DOI: --
发表时间: 2005
期刊: Anticancer Res 25(1A)
影响因子: --
作者: [Aoki D, Ueno S, Kubo F, Oyama T, Sakura T, Matsushita K, Maruyama I, Aikou T.]
通讯作者: Aikou T.
Roxithromycin inhibits constitutive activation of nuclear factor {kappa}B by diminishing oxidative stress in a rat model of hepatocellular carcinoma.
Roxithromycin 通过减少肝细胞癌大鼠模型中的氧化应激来抑制核因子 {kappa}B 的组成性激活。
DOI: --
发表时间: 2005
期刊: Clin Cancer Res 11(15)
影响因子: --
作者: [Ueno S, Kubo F, et al.]
通讯作者: et al.
6
    Basic and clinical studies regarding to the identification of inflammatory factors promoting the malignant transformation mechanism in digestive organ cancer
    • 批准号:
      23591992
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.16万
    • 财政年份:
      2011
    • 负责人:
      UENO Shinichi
    • 依托单位:
    Identification of Perpetuating Factor for Liver Tissue Inflammation in Hepatic Carcinogenesis
    • 批准号:
      19591595
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.75万
    • 财政年份:
      2007
    • 负责人:
      UENO Shinichi
    • 依托单位:
    国内基金
    海外基金
    TNFa 下调PLGF 促早发型子痫前期免疫损伤机制研究
    • 批准号:
      2021JJ30693
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2021
    • 负责人:
      吴仕元
    • 依托单位:
    基于肿瘤EMT炎症微环境的Anti-TNFa-VHH-RGD4C融合纳米抗体设计及作用机制研究
    • 批准号:
      81603017
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      19.0万元
    • 批准年份:
      2016
    • 负责人:
      纪雪梅
    • 依托单位:
    利用肿瘤穿透肽瘤内靶向递送TNFa增强抗肿瘤作用及机制研究
    • 批准号:
      81573336
    • 项目类别:
      面上项目
    • 资助金额:
      54.0万元
    • 批准年份:
      2015
    • 负责人:
      卢晓风
    • 依托单位:
    TNFa信号通路在多能干细胞造血分化中的调控作用及其机制研究
    • 批准号:
      81570098
    • 项目类别:
      面上项目
    • 资助金额:
      60.0万元
    • 批准年份:
      2015
    • 负责人:
      郑伟燕
    • 依托单位: